{
    "title": "Dandelion & Long Pepper Fruit vs Cancer",
    "inventor_name": "Sirayam PANDEY",
    "publication_year": 2015,
    "device_name": "Dandelion Root Extract",
    "goal": "Treat or prevent cancer",
    "problem_addressed": "Cancer cells and tumors (blood-related and solid cancers)",
    "concept_summary": "A water-based extract of Taraxacum (dandelion) root induces apoptosis selectively in cancer cells while sparing healthy cells. The extract has shown activity against several human cancer cell lines and in mouse xenograft models, and is currently being evaluated in a Phase 1 clinical trial for refractory hematologic malignancies.",
    "detailed_description": null,
    "principles": [
        "Induction of apoptosis",
        "Selective cytotoxicity toward cancer cells",
        "Phytochemical activity"
    ],
    "scientific_domains": [
        "Biochemistry",
        "Oncology",
        "Pharmacology"
    ],
    "mechanisms_of_action": [
        "Activation of intracellular death programs (caspase cascade)",
        "Selective targeting of cancer-specific pathways"
    ],
    "materials": [
        "Dandelion root (Taraxacum spp.)",
        "Water",
        "Solvent (e.g., ethanol)"
    ],
    "energy_sources": [],
    "inputs": [
        "Dandelion root",
        "Water",
        "Solvent"
    ],
    "outputs": [
        "Liquid root extract (DRE)",
        "Capsules containing DRE"
    ],
    "claimed_performance": "Effective against human T-cell leukemia, chronic myelomonocytic leukemia, pancreatic and colon cancers in vitro and in mouse models; no toxicity to non-cancer cells; undergoing Phase 1 clinical trials to determine safe dose and preliminary efficacy.",
    "experimental_evidence": "In-vitro studies demonstrated apoptosis in multiple cancer cell lines; mouse xenograft studies showed tumor reduction without harming normal tissue; a Phase 1 clinical trial with 30 refractory hematologic cancer patients is enrolling to assess safety, dose-limiting toxicity, and early anti-tumor activity.",
    "replication_status": "In progress - Phase 1 clinical trial ongoing; pre-clinical results have been reproduced in independent animal studies.",
    "keywords": [
        "dandelion",
        "root extract",
        "cancer",
        "apoptosis",
        "clinical trial"
    ],
    "related_technologies": [
        "Phytotherapy",
        "Natural-product drug development"
    ],
    "controversy_level": "low",
    "confidence_score": 0.9,
    "practicability_score": 0.7,
    "fringe_score": 0.1,
    "evidence_strength": 0.6,
    "risk_score": 0.2,
    "trl_estimate": 5,
    "source_urls": [
        "http://yournewswire.com/weed-destroys-cancer/",
        "http://www.uwindsor.ca/dandelionrootproject/",
        "http://windsorstar.com/news/dandelion-root-cancer-treatment-enters-clinical-trials-company-to-market-it-formed",
        "http://canadiancancertrials.ca/trial/Default.aspx?dsEndecaNav=Ntk%3AMain_en%7Cdandelion%7C1%7C%2CRo%3A0%2CNrc%3Aid-30-dynrank-disabled%7Cid-130-dynrank-disabled%7Cid-131-dynrank-disabled%7Cid-132-dynrank-disabled%7Cid-619-dynrank-disabled%7Cid-620-dynrank-disabled%7Cid-621-dynrank-disabled%7Cid-622-dynrank-disabled&TrialId=OCT1226&lang=en"
    ],
    "organizations": [
        "University of Windsor",
        "Windsor Botanical Therapeutics Inc.",
        "Advanced Orthomolecular Research"
    ],
    "applications": [
        "Cancer treatment",
        "Cancer prevention"
    ],
    "limitations": [
        "Limited clinical data (Phase 1 only)",
        "Active constituents not fully identified",
        "Potential variability in extract composition"
    ],
    "open_questions": [
        "Which specific phytochemicals are responsible for the anticancer activity?",
        "What is the optimal dosing schedule for different cancer types?",
        "What are the long-term safety and toxicity profiles?"
    ],
    "red_flags": [
        "Use of promotional language (e.g., \"astonishing results\") without peer-reviewed publications",
        "Potential over-statement of efficacy before robust clinical evidence"
    ],
    "evidence_quotes": [
        "We have observed its effectiveness against human T-cell leukemia, chronic myelomonocytic leukemia, and pancreatic and colon cancers, with no toxicity to non-cancer cells.",
        "Tests in petri dishes and in mice have shown the dandelion extract attacks the cancerous cells, but does not impact healthy ones.",
        "Dandelion root extract was approved for human trials in February 2015.",
        "The starting dose of DRE will be 1000 mg daily which will be provided by Dr. Pandey's lab at University of Windsor.",
        "The product will be available in capsule form."
    ],
    "category": "Medical & Dental Technologies"
}